|
Patent landscape, scope, and claims: |
United States Patent 5,403,856: Scope, Claim Boundaries, and US Landscape for S-Enantiomer ACE Inhibitors in Cardiac Insufficiency
What does US 5,403,856 claim, in operational terms?
US 5,403,856 is directed to methods for treating cardiac insufficiency in a mammal using an angiotensin-converting enzyme (ACE) inhibitor defined by a specific stereochemical and structural constraint.
Core claim 1 elements (the actual scope driver)
Claim 1 requires all of the following:
- Use / purpose
- “A method for treating cardiac insufficiency in a mammal”
- Patient population
- “administering to a mammal in recognized need of” the treatment
- Drug class
- “an amount of an angiotensin-converting enzyme inhibitor of the formula I, or a pharmaceutically acceptable salt thereof”
- Isomer purity
- the inhibitor or salt is “substantially free of other isomers”
- Specific formula (Formula I) with defined substituent constraints
- The patent defines Formula I with:
- n = 2
- R = phenyl
- R1 = methyl
- R2 = hydrogen, methyl, ethyl or benzyl
- R3 = hydrogen
- R4 and R5 together with their atoms form an octahydrocyclopenta[b]pyrrole ring system
- Absolute stereochemistry
- “provided that all the chiral atoms … are in the S position”
In effect, claim 1 is a stereochemically narrowed method-of-use tethered to a particular ACE inhibitor scaffold (Formula I) with S,S-only configuration and isomer purity.
Which specific embodiments are locked in by dependent claims?
Dependent claims narrow claim 1 to specific named active substances.
Claim 2 (specific stereochemically defined compound)
- N-(1-S-carbethoxy-3-phenyl-propyl)-S-alanyl-1S,3S,5S-2-azabicyclo[3.3.0]octane-3-carboxylic acid, or salt
Claim 3 (closely related specific compound)
- N-(1-S-carboxy-3-phenyl-propyl)-S-alanyl-1S,3S,5S-2-azabicyclo[3.3.0]octane-3-carboxylic acid, or salt
Claim 4 (route)
- Oral or parenteral administration
Claim 5 (formulation)
- Administration with excipients or acceptable organic/inorganic substances
Claim 6 (dose concept)
- The inhibitor is administered in a “sub-anti-hypertensive dose”
What is the functional claim scope if you are designing around it?
Claim 1 is a compound-linked method claim, so design-around focuses on breaking at least one required limitation: structure, S stereochemistry, isomer purity, ring system, or the dosing/purpose language.
1) S-enantiomer requirement is a hard boundary
- Claim 1 requires all chiral atoms in the S position.
- If a competitor product uses:
- a racemate,
- an enriched mixture that is not “substantially free of other isomers,” or
- any chiral center not exclusively S,
then claim 1 is less likely to read (and dependent claim coverage also becomes harder).
2) “Substantially free of other isomers” is a quality-control trigger
- The claim is not just “single stereoisomer”; it also requires a purity standard (“substantially free”).
- For enforceability and infringement analysis, purity is typically analyzed through:
- enantiomeric excess and stereochemical impurity profile,
- analytical method comparability,
- and product release specifications.
(Those details are not supplied in the text you provided; the scope point remains that purity is a required element.)
3) Formula I constraints are structural and limiting
- n is fixed at 2.
- R is fixed as phenyl.
- R1 is fixed as methyl.
- R3 is fixed as hydrogen.
- R4 and R5 must form the octahydrocyclopenta[b]pyrrole ring system.
- R2 allows several substituents (H, methyl, ethyl, benzyl), so there is still some substitution freedom inside that boundary.
4) Indication is “cardiac insufficiency”
- The claim’s method-of-use is for cardiac insufficiency in mammals.
- This is not “hypertension” broadly, and it is not “heart failure” textually in your excerpt, but the dosing dependent claim 6 ties the dose to being below an anti-hypertensive level.
5) Dependent claim 6 adds a dose-positioning limitation
- Claim 6 narrows further to sub-anti-hypertensive dosing.
- If a product is dosed at levels intended and labeled for antihypertensive effect, or if the clinical positioning is clearly at antihypertensive dose ranges, claim 6 becomes less relevant. Claim 1 still does not require sub-anti-hypertensive dose, but it does require the formula and stereochemical constraints.
How strong is the protection profile, claim-by-claim?
Claim 1 (strongest independent scope)
- It covers:
- all Formula I ACE inhibitors (with allowed R2 variants),
- salts,
- S stereochemistry at all chiral centers,
- and an isomer purity requirement,
- used to treat cardiac insufficiency.
- This is a broad-enough method claim to cover multiple candidates that share the same stereochemically defined scaffold and S-only purity, even if the specific named compound differs within the allowed substituent permutations.
Claims 2 and 3 (narrow embodiments)
- These are specific compounds with tight structural recitations.
- If a competitor uses a different R2 variant or a different substituent placement not covered, claim 2/3 may not read. Claim 1 may still read if the Formula I constraints match.
Claims 4 and 5 (delivery and formulation)
- These are common “no escape” dependent claims in many composition/method patents.
- They do not materially narrow beyond route/formulation typical for drug delivery.
- If a competitor uses the same API but changes route, claim 4 may be avoided, but claim 1 is not limited to oral/parenteral. Claim 5 is similarly non-material if the competitor uses different excipients, because claim 1 stands independently.
Claim 6 (dose concept)
- This claim is more about differentiation than scope capture.
- It can matter for infringement strategy if competitors deliberately dose above or below “sub-anti-hypertensive” thresholds.
Likely patent landscape dynamics in the US (based on claim architecture)
Because the independent claim ties infringement to:
1) a specific stereochemical enantiomer profile and
2) a formula-constrained ACE inhibitor scaffold and
3) a method label for cardiac insufficiency,
the US landscape will typically split into three buckets for enforcement and freedom-to-operate (FTO) analysis:
Bucket A: Same scaffold, same S-only purity, cardiac insufficiency use
- Highest infringement risk.
- Any product that uses Formula I ACE inhibitor in S-only form and is used for cardiac insufficiency can fall within claim 1.
Bucket B: Same scaffold but different stereochemistry (mixed isomers, non-S at any chiral center)
- Lower risk against claim 1 because “all chiral atoms… in S position” and “substantially free of other isomers” are gating elements.
- If a competitor sells a non-S or racemic ACE inhibitor, or uses S-enriched but not “substantially free” product, the risk depends on what “substantially free” means in practice for enforcement and how the competitor’s impurity and enantiomer profile are measured.
Bucket C: Same use but different scaffold not matching Formula I constraints
- Avoids claim 1 because structural recitations are limiting.
- Even if another ACE inhibitor treats cardiac insufficiency, it may not read unless it fits Formula I exactly.
Where does the competitive “design space” remain?
Even within Formula I, claim 1 allows multiple possibilities for R2: hydrogen, methyl, ethyl, or benzyl. That means the claim is not confined to one exact R2 substituent.
What remains closed:
- R is phenyl,
- R1 is methyl,
- R3 is hydrogen,
- n is 2,
- ring system is fixed,
- and all chiral centers are S-only.
So product variants that remain in-market under the same scaffold are likely those swapping among the allowed R2 options, while preserving S-only configuration and “substantially free” purity.
Practical infringement map (what to test against)
For any candidate ACE inhibitor intended for cardiac insufficiency, the infringement screening in a US patent portfolio usually reduces to these “pass-fail” tests:
- Does the candidate match Formula I with n=2, R=phenyl, R1=methyl, R3=H, and the octahydrocyclopenta[b]pyrrole ring system?
- Are all chiral centers S?
- Is the product substantially free of other isomers (enantiomeric and diastereomeric purity)?
- Is it administered “for the purpose” of treating cardiac insufficiency in a mammal?
- If targeting claim 6 specifically, is dosing positioned as sub-anti-hypertensive?
Key takeaways
- US 5,403,856 is a stereochemically narrowed method-of-treatment patent: it requires Formula I ACE inhibitors with S-only chiral configuration and substantially isomer-pure composition, used to treat cardiac insufficiency.
- Claim 1 is the enforcement backbone: structural Formula I constraints plus stereochemical purity and indication.
- Claims 2 and 3 lock in two specific named compounds falling under Formula I.
- Claims 4 and 5 add route/formulation limitations only as dependents; they do not restrict the core independent scope.
- Claim 6 adds a dosing differentiation point tied to sub-anti-hypertensive use, useful for competitive positioning and infringement defenses.
- Competitive risk concentrates on products that keep the same scaffold and S-only stereochemistry, and on labeling or promotion tied to treating cardiac insufficiency.
FAQs
1. Is this patent limited to a single compound?
No. Claim 1 covers ACE inhibitors of Formula I with defined ring and substituent constraints, as long as the product is S-only and substantially free of other isomers. Claims 2 and 3 add two specific compound examples.
2. Does a competitor avoid infringement by changing the route of administration?
Claim 4 is dependent. Changing from oral to parenteral (or vice versa) can avoid claim 4, but claim 1 still covers the method if the other limitations match.
3. What is the highest-risk technical variable for competitors?
Chiral purity and S configuration at all chiral centers, coupled with matching the Formula I scaffold constraints.
4. Does the patent cover treatment intended for hypertension instead of cardiac insufficiency?
The method is framed for cardiac insufficiency. Claim 6 further ties dosing to sub-anti-hypertensive levels, reinforcing the cardiac-insufficiency treatment strategy.
5. If a product is an ACE inhibitor used for cardiac insufficiency but is not “S-only,” does it still fall under this patent?
Not if it fails the gating requirements in claim 1, which require all chiral atoms in the S position and an inhibitor (or salt) that is substantially free of other isomers.
References
[1] United States Patent 5,403,856. Claims excerpt as provided in the prompt.
More… ↓
⤷ Start Trial
|
